Aktuellt
SENASTE
Redeye knew this day was coming. And still, we were caught by some surprise. FDA has granted accelerated approval to aducanumab, the first drug in Alzheimer's that targets the underlying disease pathology. We leave the first note to this news from an Alzinova perspective.
LÄS MER
